EMA/465443/2018

European Medicines Agency decision

P/0213/2018

of 17 July 2018

on the acceptance of a modification of an agreed paediatric investigation plan for arimoclomol (citrate), (EMEA-001748-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Union

European Medicines Agency decision

P/0213/2018

of 17 July 2018

on the acceptance of a modification of an agreed paediatric investigation plan for arimoclomol (citrate), (EMEA-001748-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0079/2016 issued on 18 March 2016,

Having regard to the application submitted by Orphazyme A/S on 12 March 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan and proposing a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 June 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision on the granting of a deferral.

(4) It is therefore appropriate to adopt a decision on the granting of a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for arimoclomol (citrate), capsule, hard, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A deferral for arimoclomol (citrate), capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for arimoclomol (citrate), capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Orphazyme A/S, Ole Maaløes Vej 3, 2200 – Copenhagen, Denmark.

EMA/PDCO/170760/2018 Corr
London, 1 June 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001748-PIP01-15-M01

Scope of the application

Active substance(s):

Arimoclomol (citrate)

Condition(s):

Treatment of Niemann-Pick disease, type C

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Orphazyme A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Orphazyme A/S submitted to the European Medicines Agency on 12 March 2018 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/0079/2016 issued on 18 March 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and proposed a deferral and a waiver.

The procedure started on 3 April 2018.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A waiver for a new paediatric subset has been added.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion;
   - to grant a deferral, the details of which are set out in the Annex I of this opinion;
   - to grant a waiver for one or more subsets of the paediatric population concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

Waiver

1.1. Condition:

Treatment of Niemann-Pick disease, type C

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition

Treatment of Niemann-Pick disease, type C

2.1.1. Indication(s) targeted by the PIP

Treatment of Niemann-Pick disease, type C

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	3	**Study 1** In-use stability of drug product in beverages **Study 2** In-use stability of drug product dispersed in food **Study 3** Dose recovery by administration through feeding tube of drug product dispersed in water

Non-clinical studies	3	**Study 4** Juvenile toxicity study **Study 5** Reprotoxicity (enhanced) pre- and postnatal developmental study **Study 6** Juvenile toxicity study
Clinical studies	2	**Study 7** Randomised, double-blind, placebo-controlled study to evaluate safety and efficacy of arimoclomol, in addition to best standard of care, in patients diagnosed with Niemann-Pick disease type C **Study 9** (study added in EMEA-001748-PIP01-15-M01) Open-label study to assess safety and tolerability of arimoclomol, in addition to best standard of care, in patients aged 6 to less than 24 months at study enrolment with confirmed diagnosis of NPC 1 or NPC 2
Extrapolation, modelling and simulation studies	1	**Study 8** Modelling study for optimisation of study 9
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2021
Deferral for one or more measures contained in the paediatric investigation plan:	Yes